Understanding pharmacokinetics and pharmacodynamics: Application to the antimicrobial formulary decision process

Antibiotic Optimization: Concepts and Strategies in Clinical Practice

Volumn , Issue , 2004, Pages 65-88

  Andes, David ^a   Craig, William A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28444456258     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (55)

1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1–12.
2. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988; 158:831–847.
3. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988; 157:287–298.
4. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19:261–268.
5. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279:125–129.
6. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determination. Antimicrob Agents Chemother 1998; 42:2375–2379.
7. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45:2793–2797.
8. Andes D. In vivo pharmacodynamics of antifungal drugs in the treatment of candidiasis. Antimicrob Agents Chemother 2003; 47:1179–1186.
9. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33(Suppl 3):S233-S237.
10. Dudley MN, Ambrose PG. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr Opin Microbiol 2000; 3: 515–521.
11. Vesga O, Craig WA. Impact of macrolide resistance on the in vivo activity of a new ketolide, HMR 3647, against S. pneumoniae and S. aureus [abstr F259], 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Sept 28-Oct 1, 1997.
12. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255–259.
13. Dowell SF, Butler JC, Giebink GS, Jacobs MR, Jernigan D, Musher DM, Rakowsky A, Schwartz B. Acute otitis media: management and surveillance in an era of pneumococcal resistance—report from the Drug-Resistant Streptococcus Pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18:1–9.
14. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drugresistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med 2000; 160:1399–1408.
15. Whitney CG. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000; 123: 1–32.
16. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; 74(Suppl):63–70.
17. Craig WA, Gudmundsson S. Postantibiotic Effect. In: Lorian V, Ed Antibiotics in Laboratory Medicine. 4th ed. Baltimore: Williams & Wilkins, 1996:296–329.
18. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054–1060.
19. Craig WA, Kiem S, Andes DR. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides, and clindamycin [abstr A-1264], 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sept 27–30, 2002.
20. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483–490.
21. Lacy MK, Lu W, Xu X, Tessier PR, Nicolau DP, Quintiliani R, Nightingale CH. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999; 43:672–677.
22. Lacy MK, Nicolau DP, Nightengale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27: 23–27.
23. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA. Comparative dose-effect relationships at several dosing intervals in murine pneumonitis and thighinfection models. J Infect Dis 1989; 159:281–292.
24. Leggett JE, Ebert S, Fantin B, Craig WA. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 1990; 74:179–184.
25. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–99.
26. Craig WA. Interrelationships between pharmacokinetics and pharmacodynamics in determining dosage regimens for broadspectrum cephalosporins. Drug Microbiol Infect Dis 1995; 22: 89–93.
27. Andes D, Peng J, Craig WA. In vivo characterization of the pharmacodynamics of a new oxazolidinone (linezolid). Anti microb Agents Chemother 2002; 46:3484–3489.
28. Christianson J, Andes D, Craig W. Characterization of the pharmacodynamics of clindamycin against Streptococcus pneumoniae in a murine thigh infection model [abstr], 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Dec 16–19, 2001.
29. Christianson J, Andes D, Craig W. Magnitude of the 24h AUC/MIC required for doxycycline against Streptococcus pneumoniae in a murine thigh infection model [abstr], 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Dec 16–19, 2001.
30. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786–795.
31. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073–1081.
32. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43:79–86.
33. Preston SL, Drusano GL, Berman AL. Levofloxacin population pharmacokinetic and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother; 1998:1098–1104.
34. Dagan R, Leibovitz E, Fliss DM, Leiberman A, Jacobs MR, Craig W, Yagupsky P. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44:43–50.
35. Dagan R, Johnson CE, McLinn S, Abughali N, Feris J, Leibovitz E, Burch DJ, Jacobs MR. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19:95–104.
36. Dagan R, Hoberman A, Johnson C, Leibovitz EL, Arguedas A, Rose FV, Wynne BR, Jacobs MR. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001; 20:829–837.
37. Woodnut G, Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulante against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43:29–34.
38. Craig WA, Suh B. Protein Binding. In: Lorian V, Ed Antibiotics in Laboratory Medicine. 3d ed. Baltimore: Williams & Wilkins, 1991:367–402.
39. Kunin CM, Craig WA, Kornguth M, Monson R. Influence of binding to the pharmacologic activity of antibiotics. Ann NY Acad Sci 1973; 226:214–224.
40. File TM Jr, Jacobs MR, Poole MD, Wynne B. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxicillin/clavulanate. Int J Antimicrob Agents 2002; 20:235–247.
41. Ambrose PG, Quintiliani R, Nightingale CH. Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia. Infect Dis Clin Prac 1997; 7:463–470.
42. Vesga O, Andes D, Craig WA. Comparative in vivo activity of HMR 3647, azithromycin, clarithromycin, and roxithromycin against S. pneumoniae and S. aureus [abstr F258], 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Sept 28-Oct 1, 1997.
43. Andes D, Craig WA. Pharmacokinetics of fluoroquinolones in experimental endocarditis. Clin Infect Dis 1998; 27:47–50.
44. Andes D, Craig WA. Characterization of the pharmacodynamics of the new fluoroquinolone, gatifloxaxin, in murine thigh and lung infection models. Antimicrob Agents Chemother 2002; 46:1665–1670.
45. Nicolau DP, Mattoes HM, Banevicius M, Xuan D, Nightingale CH. Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model. Antimicrob Agents Chemother 2003; 47:1630–1635.
46. Kashuba ADM, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623–629.
47. Rybak MJ, Abate BJ, Kang SL, Ruffing ML, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549–1555.
48. Verpooten GA, Biulinao RA, Verbist L, Eestermans G, De Broe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45:22–27.
49. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL, for the NCCLS Subcommittee on Antifungal Susceptibility Testing. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro and in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235–247.
50. Ambrose PG, Garsela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 38:151–157.
51. Garsela DM. NCCLS Document M100-S11: Performance Standards for Antimicrobial Susceptibility Testing; Eleventh Informational Supplement. Philadelphia: NCCL, 2001.
52. Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003; 52:435–440.
53. Ambrose PG, Quintiliani R. Limitations of single point pharmacodynamic analysis. Pediatr Infect Dis J 2000; 19:769.
54. Bonate PL. A brief introduction to Monte Carlo simulation. Clin Pharmacokinet 2001; 40:15–22.
55. http://FDA.gov/cder/guidance/2580dft.pdf.